Description

6,8-Methanoquinoline, 2-[(4S)-4,5-Dihydro-4-Phenyl-2-Oxazolyl]-5,6,7,8-Tetrahydro-7,7-Dimethyl-, (6R,8R)- is a complex, stereochemically defined organic compound that serves as a high-value chiral building block and advanced pharmaceutical intermediate. Its intricate fused-ring structure, incorporating methanoquinoline and oxazoline moieties, makes it a critical precursor for the synthesis of novel bioactive molecules. This compound is primarily utilized by pharmaceutical R&D and fine chemical synthesis teams focused on developing new therapeutic agents, particularly in areas requiring precise stereochemical control.

Application

• Pharmaceutical Intermediate: Key chiral synthon for the research and development of new active pharmaceutical ingredients (APIs), especially in central nervous system (CNS) and anti-infective drug candidates.
• Asymmetric Catalysis Ligand Precursor: The oxazoline ring can be modified to create novel chiral ligands for asymmetric synthesis, enabling the production of enantiomerically pure compounds.
• Medicinal Chemistry Research: Used as a core scaffold or building block in structure-activity relationship (SAR) studies and combinatorial chemistry libraries to explore new biological targets.
• Fine Chemical Synthesis: Employed in multi-step organic syntheses requiring complex, polycyclic frameworks with specific stereochemistry.
• Academic & Industrial R&D: Serves as a reference standard and starting material in chemical research focused on heterocyclic and natural product-like compounds.

Basic Information

Item	Details
Product Name	6,8-Methanoquinoline, 2-[(4S)-4,5-Dihydro-4-Phenyl-2-Oxazolyl]-5,6,7,8-Tetrahydro-7,7-Dimethyl-, (6R,8R)-
CAS No.	1027754-31-9
Molecular Formula	C23H26N2O
Molecular Weight	346.47 g/mol
Synonyms	(6R,8R)-2-[(4S)-4,5-Dihydro-4-phenyl-2-oxazolyl]-7,7-dimethyl-5,6,7,8-tetrahydro-6,8-methanoquinoline; 2-[(4S)-4,5-Dihydro-4-phenyl-2-oxazolyl]-5,6,7,8-tetrahydro-7,7-dimethyl-6,8-methanoquinoline, (6R,8R)-; (6R,8R)-2-((S)-4,5-Dihydro-4-phenyloxazol-2-yl)-7,7-dimethyl-5,6,7,8-tetrahydro-6,8-methanoquinoline; CAS 1027754-31-9; 6,8-Methanoquinoline derivative; Chiral oxazoline-quinoline hybrid; Fused tricyclic oxazoline compound.
EINECS	Contact for details

Quality Control

Our production of this high-purity chiral intermediate adheres to stringent quality protocols. Every batch undergoes comprehensive analytical testing, including Chiral HPLC to confirm enantiomeric excess and NMR for structural verification. We provide a detailed Certificate of Analysis (COA) with each shipment, documenting purity, identity, and impurity profiles. Our quality system is designed to meet the exacting standards of pharmaceutical R&D and GMP-guided synthesis.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (typically 15-25°C). For long-term storage under inert atmosphere, please contact our technical team for specific recommendations. Keep away from strong oxidizing agents.

Specification

Item	Specification
Appearance	White to off-white crystalline powder
Identification (HPLC)	Conforms to reference standard
Identification (IR)	Conforms to structure
Purity (HPLC)	≥ 98.0%
Chiral Purity (Chiral HPLC)	≥ 99.0% e.e.
Water Content (KF)	≤ 0.5%
Residue on Ignition	≤ 0.1%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.